Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions International, Inc. (TSOI) generates a steady flow of news centered on immune modulation, stem cell therapy, immunotherapy, and nutraceutical development. This news page aggregates company announcements so readers can follow how its clinical-stage programs, patents, and subsidiaries evolve over time.
Recent press releases highlight progress with the company’s JadiCell universal donor stem cell product in areas such as lung inflammation, COVID-19–related conditions, ARDS, epilepsy, and ALS. News items also cover mechanistic discoveries about how JadiCells interact with immune cells, as well as data suggesting that these cells may enhance gene therapy–mediated production of therapeutic cells.
Another major stream of updates involves the nutraceutical QuadraMune. The company has announced multiple patents related to QuadraMune’s effects on immune pathways, including natural killer cell activity, viral inhibition, brain protection, and modulation of regulatory T cells. These developments are reflected in patent-related news and scientific commentary from company representatives.
Therapeutic Solutions International also issues news about its subsidiaries and pre–spin-off entities, such as Campbell Neurosciences in suicide prevention, Res Nova Bio in oncology immunotherapy, Epilepsy Bio in epilepsy, and ALS Biologics in ALS. Announcements may describe clinical observations under Right To Try, plans for public listings, loyalty dividends of subsidiary shares, and strategic positioning of intellectual property.
In addition, the company has released statements on legal actions and corporate decisions, including its plan to voluntarily delist and "go dark" from the public markets. Investors and observers can use this news feed to review historical announcements on clinical progress, patents, subsidiary formation, legal matters, and capital markets strategy related to TSOI.
Therapeutics Solution International (OTC: TSOI) announced the filing of a patent showing synergy between QuadraMune™ and Minocycline in generating T regulatory cells, which help suppress inflammation. This is significant for conditions like suicidal ideation and COVID-19 mortality risks. QuadraMune™, currently in clinical trials for COVID-19 prevention, could aid in developing treatments for suicides from an immunological viewpoint. The combination may offer long-lasting therapeutic effects against neuroinflammation, with potential applications in other neurodegenerative diseases.
Therapeutics Solutions International (OTC: TSOI) has filed a patent for the Campbell Score™, a groundbreaking method for assessing suicide risk through immunological parameters in blood samples. With an alarming estimate of 1.5 million lives lost to suicide in 2020, the company aims to shift the stigma surrounding mental health by scientifically linking suicidal tendencies to immune health. Director Kalina O'Connor, driven by personal tragedy, states that current evaluation methods are unreliable. The company also explores the use of QuadraMune™ to reduce inflammatory responses related to suicidal ideations.